12:00 AM
 | 
Aug 08, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lebrikizumab: Phase II data

The double-blind Phase II MILLY trial in 218 patients with asthma inadequately controlled with inhaled corticosteroids showed that subcutaneous lebrikizumab met the primary endpoint of significantly improving the mean relative change in FEV1 from baseline to week 12 vs. placebo (9.8% vs. 4.3%, p=0.02). On secondary endpoints, lebrikizumab significantly improved the mean absolute change in FEV1 from baseline to week 12 vs. placebo (0.2 vs. 0.09 liters, p=0.02). Lebrikizumab non-significantly reduced the rate of severe asthma exacerbations through...

Read the full 370 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >